, Volume 85, Issue 3, pp 191-193
Date: 20 Dec 2005

Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear editor,

Multiple myeloma (MM) is a malignant disorder characterized by an uncontrolled clonal proliferation of malignant bone marrow (BM) plasma cells producing a monoclonal paraprotein which is readily detectable both in serum and urine in the majority of patients. MM is associated with lytic bone lesions, renal function impairment and immunodeficiency caused by myelosuppression. With effective treatment, the median overall survival (OS) is approximately 4 years. The central goal in improving MM treatment is the achievement of a prolonged complete remission (CR), long-term OS and improvement of the quality of life, with few, if any, MM-associated symptoms [110]. Over the last years, high-dose (HD) chemotherapy (Ctx) followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) has emerged as one very effective approach to reach these therapeutic goals [14]. HD regimens have previously changed from busulphan and cyclophosphamide (Bu/Cy) to HD melphalan (MEL), wit ...